EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumini Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson

Research output: Contribution to journalArticle

7754 Citations (Scopus)

Abstract

Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

Original languageEnglish
Pages (from-to)1497-1500
Number of pages4
JournalScience
Volume304
Issue number5676
DOIs
Publication statusPublished - 2004 Jun 4

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy'. Together they form a unique fingerprint.

  • Cite this

    Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. (2004). EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497-1500. https://doi.org/10.1126/science.1099314